RBC Capital Cuts Epizyme (NASDAQ:EPZM) Stock To a “Sector Perform” Rating

November 14, 2017 - By Richard Conner

 RBC Capital Cuts Epizyme (NASDAQ:EPZM) Stock To a

Investors sentiment increased to 1.93 in 2017 Q2. Its up 0.87, from 1.06 in 2017Q1. It is positive, as 13 investors sold Epizyme Inc shares while 17 reduced holdings. 25 funds opened positions while 33 raised stakes. 47.46 million shares or 3.38% more from 45.91 million shares in 2017Q1 were reported.

32,291 are held by Strs Ohio. Trexquant Inv L P owns 12,206 shares or 0.05% of their US portfolio. State Board Of Administration Of Florida Retirement has invested 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Moreover, Voya Mngmt Ltd Liability Corp has 0.02% invested in Epizyme Inc (NASDAQ:EPZM). Nea Mgmt Company Llc has invested 3.44% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Gp One Trading L P has 0% invested in Epizyme Inc (NASDAQ:EPZM). Numeric Investors Ltd Liability has 0% invested in Epizyme Inc (NASDAQ:EPZM) for 24,900 shares. Jennison Associate Limited Liability Corporation reported 0.03% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Loring Wolcott And Coolidge Fiduciary Advisors Limited Liability Partnership Ma invested in 0% or 3,000 shares. Iguana Health Llc holds 75,000 shares or 0.64% of its portfolio. Royal Bank & Trust Of Canada owns 0% invested in Epizyme Inc (NASDAQ:EPZM) for 1,955 shares. Rhenman & Asset has 0.55% invested in Epizyme Inc (NASDAQ:EPZM). Geode Management Ltd Llc holds 0% or 353,514 shares. Baker Bros Advisors L P stated it has 232,481 shares or 0.03% of all its holdings. State Street, Massachusetts-based fund reported 1.76M shares.

Since May 25, 2017, it had 0 buys, and 2 sales for $275,289 activity. $33,625 worth of Epizyme Inc (NASDAQ:EPZM) was sold by Copeland Robert A on Tuesday, June 6.

Epizyme (NASDAQ:EPZM) Receives a Downgrade

In a research note made public today, RBC Capital downgraded shares of Epizyme (NASDAQ:EPZM) to a “Sector Perform” rating from the previous “Outperform” rating.

Investors sentiment increased to 1.93 in 2017 Q2. Its up 0.87, from 1.06 in 2017Q1. It is positive, as 13 investors sold Epizyme Inc shares while 17 reduced holdings. 25 funds opened positions while 33 raised stakes. 47.46 million shares or 3.38% more from 45.91 million shares in 2017Q1 were reported.

32,291 are held by Strs Ohio. Trexquant Inv L P owns 12,206 shares or 0.05% of their US portfolio. State Board Of Administration Of Florida Retirement has invested 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Moreover, Voya Mngmt Ltd Liability Corp has 0.02% invested in Epizyme Inc (NASDAQ:EPZM). Nea Mgmt Company Llc has invested 3.44% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Gp One Trading L P has 0% invested in Epizyme Inc (NASDAQ:EPZM). Numeric Investors Ltd Liability has 0% invested in Epizyme Inc (NASDAQ:EPZM) for 24,900 shares. Jennison Associate Limited Liability Corporation reported 0.03% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Loring Wolcott And Coolidge Fiduciary Advisors Limited Liability Partnership Ma invested in 0% or 3,000 shares. Iguana Health Llc holds 75,000 shares or 0.64% of its portfolio. Royal Bank & Trust Of Canada owns 0% invested in Epizyme Inc (NASDAQ:EPZM) for 1,955 shares. Rhenman & Asset has 0.55% invested in Epizyme Inc (NASDAQ:EPZM). Geode Management Ltd Llc holds 0% or 353,514 shares. Baker Bros Advisors L P stated it has 232,481 shares or 0.03% of all its holdings. State Street, Massachusetts-based fund reported 1.76M shares.

Since May 25, 2017, it had 0 buys, and 2 sales for $275,289 activity. $33,625 worth of Epizyme Inc (NASDAQ:EPZM) was sold by Copeland Robert A on Tuesday, June 6.

Epizyme Inc (NASDAQ:EPZM) Ratings Coverage

Among 11 analysts covering Epizyme (NASDAQ:EPZM), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Epizyme has $42 highest and $17 lowest target. $23.80’s average target is 82.38% above currents $13.05 stock price. Epizyme had 28 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, August 6 by Mizuho. Citigroup initiated it with “Buy” rating and $17 target in Tuesday, April 5 report. The rating was maintained by Oppenheimer on Tuesday, August 1 with “Buy”. SunTrust maintained it with “Buy” rating and $21.0 target in Friday, October 27 report. The firm has “Buy” rating given on Friday, August 4 by RBC Capital Markets. The stock of Epizyme Inc (NASDAQ:EPZM) earned “Buy” rating by Oppenheimer on Monday, July 24. Leerink Swann maintained the stock with “Buy” rating in Thursday, June 15 report. RBC Capital Markets downgraded Epizyme Inc (NASDAQ:EPZM) on Thursday, November 2 to “Sector Perform” rating. The stock of Epizyme Inc (NASDAQ:EPZM) earned “Buy” rating by H.C. Wainwright on Thursday, June 15. The firm has “Buy” rating given on Thursday, November 2 by Leerink Swann.

About 25,009 shares traded. Epizyme Inc (NASDAQ:EPZM) has risen 91.85% since November 14, 2016 and is uptrending. It has outperformed by 75.15% the S&P500.

Analysts await Epizyme Inc (NASDAQ:EPZM) to report earnings on March, 8. They expect $-0.57 earnings per share, up 5.00 % or $0.03 from last year’s $-0.6 per share. After $-0.63 actual earnings per share reported by Epizyme Inc for the previous quarter, Wall Street now forecasts -9.52 % EPS growth.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $904.14 million. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. It currently has negative earnings. The Firm is engaged in the discovery and development of novel epigenetic therapies for cancer patients.

More recent Epizyme Inc (NASDAQ:EPZM) news were published by: Globenewswire.com which released: “Epizyme to Present at the Jefferies 2017 London Healthcare Conference” on November 01, 2017. Also Globenewswire.com published the news titled: “Epizyme Reports Third Quarter 2017 Operating Results and Company Updates” on November 01, 2017. Globenewswire.com‘s news article titled: “Epizyme Announces Date of Third Quarter 2017 Financial Results” with publication date: October 25, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.